Pantocure™ 20Tablet: Each tablet contains Pantoprazole Sodium Sesquihydrate BP equivalent to Pantoprazole 20 mg.
Pantoprazole, a substituted benzimidazole, is an inhibitor of gastric acid secretion. Pantoprazole inhibits secretion of gastric acid by blocking the hydrogen-potassium-adenosine triphosphatase enzyme system, the so called 'Proton Pump' of the gastric parietal cell. Absorption of Pantoprazole begins only after the tablet leaves the stomach. Peak serum concentration (Cmax) and area under the serum concentrationtime curve (AUC) increase in a manner proportional to oral dose from 1O mg to 80 mg. Pantoprazole does not accumulate and its pharmacokinetics are unaltered with multiple daily dosing. Following oral administration, the serum concentration of Pantoprazole declines biexponentially with a termina l elimination half-life of approximately one hour. The absorption of Pantoprazole is rapid, with a Cmax of 2.5 mcg/ml, which occurs approximately 2.5 hours after single or multiple oral 40 mg doses. Pantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximate ly 77%. Administration of Pantoprazole with food may delay its absorption up to 2 hours or longer. However, the Cmax and the extent of Pantoprazole absorption (AUC) are not altered. Thus, Pantoprazole may be taken without regard to timing of meals. The serum protein binding of Pantoprazole is about 98%, primarily to albumin. Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. After a single oral dose of 14C-labeled Pantoprazole to healthy, normal metabolizer volunteers, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion. There was no renal excretion of unchanged Pantoprazole.
Benign gastric ulcer, duodena l ulcer, gastroesophageal reflux disease (GERD), NSAID-induced peptic ulcer, acid hypersecretory conditions including Zollinger - Ellison Syndrome, eradication of Helicobacter pylori(in combination with antibiotics), ulcer resistant to H2 receptor antagonists.
|Manufactured By||Rangs Pharma|